Acadia’s schizophrenia treatment misses late-stage main goal; shares fall 16%
Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.
- Britain calls for European naval mission to counter Iran’s ‘piracy’
- Wizards expected to offer All-Star G Beal an extension